BM
Biomea Fusion, Inc.
BMEA · NASDAQ
$1.71 -0.29% (-$0.01)
1M +7.55%
Market Cap $123.6M
P/E Ratio -
Div. Yield -
ROE 171.19%
Bulios Fair Price
$1.33
22.2% downside
Current Price
$1.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BMEA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
0/9Valuation
0 /100
Expensive P/B 10.19x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 35.19%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 212.95%
Asset turnover 0.00x
ROE 171.19%
Debt
100 /100
Low Debt/Equity 0.07x
Current ratio 3.47x
Int. coverage N/A
Stability
35 /100
Moderate Beta -0.30x
Profitable years 0
EPS volatility 50.15%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BMEA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael J. Hitchcock
Employees
37
Headquarters
San Carlos
Upcoming events
03 NOV
Earnings
Upcoming earnings report